This KDIGO Guideline, entitled Management of Blood Pressure in Chronic Kidney Disease, is the result of these efforts. Scope of this guideline This Guideline has been developed to provide advice on the management of BP in patients with non dialysis-dependent CKD (CKD ND) (see Reference Keys). BP. We have avoided using the term hypertension in our title because this implies that there is a BP value above or below which morbidity or mortality changes in a stepwise fashion, hence suggesting that it is possible to set a universal BP target. In reality, it proved difficult to define precise targets appropriate for all CKD subpopulations, consistent with the notion that the ideal BP may differ between patients, once other factors are considered. These factors include specific features of CKD such as the severity of albuminuria or proteinuria, the presence of other risk factors for cardiovascular disease (CVD) and co- morbidities. Another reason for our choice of terminology is that agents introduced primarily to treat high BP may have actions that may not be directly linked to BP-lowering (e.g., the anti-albuminuric effects of angiotensin-converting enzyme inhibitors [ACE-Is] and angiotensin-receptor blockers [ARBs]). Definition of CKD. The Work Group defined CKD according to the standard KDOQI classification system2 as endorsed by KDIGO.3 Populations of interest. 